A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity

被引：68

作者：

Carrion, Ricardo, Jr.

Patterson, Jean L.

Johnson, Curtis

Gonzales, Monica

Moreira, Carmen R.

Ticer, Anysha

Brasky, Kathleen

Hubbard, Gene B.

Moshkoff, Dmitry

Zapata, Juan

Salvato, Maria S.

Lukashevich, Igor S.

机构：

[1] Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA

[2] SW Fdn Biomed Res, San Antonio, TX 78284 USA

来源：

VACCINE | 2007年 / 25卷 / 20期

关键词：

lassa fever; reassortant vaccine; cross-protection; sterilizing immunity;

D O I：

10.1016/j.vaccine.2007.02.038

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Lassa virus (LASV) is responsible for the deaths of thousands of people in West Africa annually. Genetic diversity among LASV strains is the highest among the Arenaviridae and represents a great challenge for vaccine development. Guinea pigs vaccinated with a ML29 reassortant vaccine experienced sterilizing immunity and complete protection when challenged on day 30 either with homologous virus or with the distantly related Nigerian isolate. Simultaneous vaccination-challenge or challenge on day 2 after vaccination also protected 60-100% of the animals against both strains, but without sterilizing immunity. These results indicate that simultaneous replication of ML29 and LASV attenuates the virulence of LASV infection. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：4093 / 4102

页数：10

共 77 条

[71] Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones [J].